VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2021 | CAR-T moving forwards for r/r DLBCL

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, gives an overview of first line therapies and the role of stem cell transplantation and chimeric antigen receptor (CAR-T) therapy in the treatment of diffuse large B-cell lymphoma (DLBCL). Dr Sureda reports that CAR-T therapy will significantly impact the treatment of patients with DLBCL who are relapsed/refractory (r/r) after the first line of treatment. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Transcript (edited for clarity)

So, that was a workshop that basically tried to give an overview on first-line treatment and some uncertainties in patient with diffuse large B-cell lymphoma and was also very much focused on the role of stem cell transplantation, both autologous and allogeneic stem cell transplant and the position of CAR T-cells in the treatment of diffuse large B-cell lymphoma. Probably from a transplant point of view because we are usually not transplanting patients that achieve a first complete remission...

So, that was a workshop that basically tried to give an overview on first-line treatment and some uncertainties in patient with diffuse large B-cell lymphoma and was also very much focused on the role of stem cell transplantation, both autologous and allogeneic stem cell transplant and the position of CAR T-cells in the treatment of diffuse large B-cell lymphoma. Probably from a transplant point of view because we are usually not transplanting patients that achieve a first complete remission.

The summary is that the way that we are treating these patients that are primary refractory or that relapse after first-line treatment will be significantly modified with the advent of CAR T-cells that are already established, and they have a clinical indication in patients that had failed at least two prior lines of treatment. And that eventually and depending on the results of three different prospective clinical trials, one of them ongoing, the other two have already been closed, maybe CAR T-cells will be moved in earlier phases of the disease. And there was quite a good discussion surrounding how we had to bridge patients into CAR-T, and some, specific issues in this setting.

Read more...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter